Revenue during the quarter grew 16.28 percent to $2,980.50 million from $2,563.30 million in the previous year period. Gross margin for the quarter expanded 30 basis points over the previous year period to 96.19 percent. Total expenses were 68.80 percent of quarterly revenues, up from 64.88 percent for the same period last year. That has resulted in a contraction of 392 basis points in operating margin to 31.20 percent.

Operating income for the quarter was $929.90 million, compared with $900.20 million in the previous year period.

“2016 was an outstanding year of progress strengthening our commercial portfolio and advancing our early-, mid- and late-stage pipeline,” said Mark J. Alles, Celgene’s Chief Executive Officer. “We expect our business momentum and significant near-term catalysts to drive high-growth through 2017 and beyond.”

For fiscal year 2017, Celgene Corp projects revenue to be in the range of $13,000 million to $13,400 million. Celgene Corp expects net income to be in the range of $4,767.80 million to $5,060.50 million and adjusted net income to be in the range of $5,786.50 million to $5,908.80 million. The company projects operating income to grow at 45.50 percent and projects adjusted operating income to grow at 56.50 percent. It forecasts diluted earnings per share to be in the range of $5.85 to $6.21and forecasts diluted earnings per share to be in the range of $7.10 to $7.25 on adjusted basis.